Nutrition Guide

Solute carrier family 16, member 2 (monocarboxylic acid transporter 8), also known as SLC16A2, is a human gene.[1]

DnaJ (Hsp40) homolog, subfamily C, member 13, also known as DNAJC13, is a human gene.[1]

Since the reticuloendothelial system will remove the haptoglobin-hemoglobin complex from the body, haptoglobin levels will be decreased in hemolytic anemias. In the process of binding hemoglobin, haptoglobin sequesters the iron within hemoglobin, preventing iron-utilizing bacteria from benefitting from hemolysis. It is theorized that because of this, haptoglobin has evolved into an acute phase protein.

A nitrocellulose slide, nitrocellulose membrane or nitrocellulose paper is a sticky membrane used for immobilizing nucleic acids in Southern blots and Northern blots. It is also used for immobilization of proteins in Western blots, due to its non-specific affinity for amino acids. Nitrocellulose is widely used as support in diagnostic tests where antigen-antibody binding occur, e.g., pregnancy tests, U-Albumin tests and CRP. Glycine and chloride ions make protein transfer more efficient.
When dissolved in ether or other organic solvents, the solution is called collodion, which has been used as a wound dressing and carrier of topical medications since the U.S. Civil War. To this day, it is used in Compound W Wart Remover as a carrier of salicylic acid, the active ingredient.
Collodion was also used as the carrier for silver salts in some very early photographic emulsions, particularly spread in thin layers on glass plates.
Magician’s flash paper, sheets of paper or cloth made from nitrocellulose, which burn almost instantly, with a bright flash, and leave no ash.
Radon tests for alpha track etches
Nitrocellulose lacquer was used as a finish on guitars for most of the 20th century and is still used on some current applications. Manufactured by (among others) Dupont, the paint was also used on automobiles sharing the same color codes as many guitars including Fender and Gibson brands.[1]
Nitrocellulose lacquer is also used as an aircraft dope, painted onto fabric-covered aircraft to tauten and provide protection to the material.
As a transportation medium for one-time pads, thus making the disposal of the pad complete, secure, and efficient.

Dimiracetam is a nootropic drug of the racetam family,[1] derivatives of which may have application in the treatment of neuropathic pain.[2]

After a confirmed test of the anxiolytic efficacy in a mouse model, receptor antagonists haloperidol, mecamylamine, and ketanserin were applied. Haloperidol completely reversed the anxiolytic effects, and mecamylamine and ketanserin nearly completely reversed the effects. This shows that aniracetam’s anxiolytic mechanism is facilitated by D2/D3 dopamine, nicotinic acetylcholine, and 5-HT2A receptors[1].

Aniracetam has also been shown to selectively modulate the AMPA glutamate receptor[2] and was used as the parent compound to derive a class of drugs known as the ampakines which are being investigated as nootropics and neuroprotective drugs for the treatment of Alzheimer’s disease and other neurodegenerative conditions.1

Despite the fat solubility of aniracetam its half-life is much shorter than common racetam analogs such as Piracetam.

Commonly used doses are 750-3,000 mg daily usually taken in 2-3 doses.

Side effects:

Nausea, headache, etc.

[edit]
See also

Aniracetam (Draganon, Sarpul, Ampamet) is a nootropic compound of the racetam family purported to be considerably more potent than piracetam. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer’s patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models. Sold in the US as a dietary supplement while used in Europe as a prescription drug.

Aniracetam is an ampakine class Nootropic.

LY-503,430 is an ampakine drug developed by Eli Lilly.[1]

LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson’s Disease although it has also been proposed to be useful in the treatment of Alzheimer’s Disease, depression and schizophrenia.[4][5]

IDRA-21 is an ampakine drug derived from aniracetam. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form.[1]

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30x more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine,[2][3] and produces sustained effects lasting for up to three days after a single dose.[4] The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.[5]

IDRA-21 does not produce neurotoxicity under normal conditions,[6] although it may worsen neuronal damage following global ischemia after stroke or seizures.[7]

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546.[8] Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed,[9][10] but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX- series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.[11]

[edit]
References

Farampator (CX-691, ORG-24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer’s Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. [1]